Activator of G-protein signaling 8 (AGS8), also known as fibronectin type III domain containing 1 (FNDC1), is an accessory protein for heterotrimeric G-proteins involved in various cellular processes. The interaction between AGS8 and Gβγ subunit is a critical step in AGS8-mediated signaling, and a peptide that disrupts this interaction inhibited angiogenic events. To explore the broader potential of AGS8 biology, we investigated small molecules that block the AGS8-Gβγ interaction. Using a yeast-based system, in which cell growth depends on AGS8-mediated activation of G-protein pathway, we screened compounds from the RIKEN NPDepo library and identified one compound that effectively inhibited the formation of the AGS8-Gβγ complex. Consistent with the effects observed in AGS8 knockdown or peptide-treated cells, this compound attenuated VEGF-induced phosphorylation of signaling molecules and inhibited tube formation and migration of HUVECs. These data demonstrate the potential of the AGS8 inhibitor as a research tool and a therapeutic application.
Building similarity graph...
Analyzing shared references across papers
Loading...
Alamgir Hossain
Aya Yamamura
Rie Takahashi
The Journal of Physiological Sciences
RIKEN Center for Sustainable Resource Science
Aichi Medical University
Building similarity graph...
Analyzing shared references across papers
Loading...
Hossain et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69a76046c6e9836116a2cdcc — DOI: https://doi.org/10.1016/j.jphyss.2026.100064
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: